BSD Medical Announces Shipment of Third BSD-2000 Hyperthermia System to Taiwan Distributor

  BSD Medical Announces Shipment of Third BSD-2000 Hyperthermia System to
  Taiwan Distributor

BSD has Sold Three BSD-2000 Hyperthermia Systems to Linden Bioscience since
Linden Obtained Taiwan Food and Drug Administration (TFDA) Marketing Approval
in February 2014

Business Wire

SALT LAKE CITY -- June 2, 2014

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that BSD has shipped three of four BSD-2000 Hyperthermia
Systems (BSD-2000) ordered by its exclusive Taiwan distributor, Linden
Bioscience Co., Ltd (Linden). Linden is a leading distributor of sophisticated
medical devices in Taiwan. The Company shipped the first two BSD-2000 systems
to Linden in February 2014. BSD plans to ship the fourth BSD-2000 to Linden by
August 31, 2014.

“We are pleased to sell another BSD-2000 system to Linden,” stated Sam
Maravich, Vice President of International Sales and Marketing of BSD Medical.
“Linden is working with key prestigious Taiwanese hospitals for installation
of the first BSD-2000 systems. Linden is also working diligently with notable
key opinion leaders in Taiwan to further expand awareness of the clinical
benefits of the BSD-2000,” concluded Mr. Maravich.

There is a substantial marketing opportunity for BSD's products in Taiwan,
which is one of the most advanced medical device markets in Asia. The total
medical device market in Taiwan is estimated to be approximately $1.6 billion.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
Fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.